The disease
Gout: a chronic disease that causes extremely painful and disabling inflammatory attacks
Gout affects more than 50 million people worldwide, including more than 10 million people in the United States
Many patients have comorbidities that limit the use of currently available treatments for gout flares
Treatments for gout flares are often insufficiently effective, too slow to act, or unsuitable for many patients
A significant unmet medical need remains in the management of gout flares in the most difficult-to-treat patients
Our solution
A fast-acting, highly effective and safe treatment
A unique intra-articular combination, administered directly into the affected joint, combining:
- Ropivacaine for rapid pain relief
- Controlled-release colchicine for long-lasting control of inflammation
Administration
1
Single administration
per flare in all joints
Onset
Immediate
Minutes,
rapid onset of relief
Duration
7 days
Pain killer over the whole
flare duration (7 days)
Eligibility
All patients
Suitable for all refractory
gout patients
Derisked development program
Validated mechanism of action in humans
Colchicine: an oral treatment already approved
for gout flares.
Its clinical use is constrained by a narrow therapeutic window, highlighting the need for the development of a targeted local administration strategy.
Ropivacaine: a recognized treatment already
on the market for providing rapid analgesia
Clinical Program
Clearance from FDA to initiate the clinical
program directly by a Phase 2 study
Support
High efficiency and transposition
Robust preclinical pharmacokinetic and efficacy data
Local pathology, local mechanisms:
high probability of translatability to humans
Strongly supported by key opinion leaders
Key opinion leaders
"This product will fill a much needed gap in gout flare treatments: an effective, safe alternative for all patients but mainly for those who have contraindications to other therapies"
Pr. Angelo Gaffo
Rheumatoglogist
@Birmingham VA Hospital, USA
"An encapsulated colchicine with local release represents a major advance in the management of flares"
Pr. Hang-Korng Ea
Rheumatologist
@Hopital Lariboisière
Paris, France
"This new product is a breakthrough in the treatment of gout flares. The rapid onset should improve patient - physician confidence and adherence to treatments"
Pr. M-C. Boissier
Rheumatologist @AP-HP
Paris, France
"An injectable form of colchicine as a concept is innovative and would represent a very useful
form of therapy for acute gout"
Pr. Geraldine McCarthy
Rheumatologist @University College Dublin, Ireland
An extension of ARTHRELIS to osteoarthritis
The disease
Over 600 million people worldwide
A highly prevalent degenerative disease for which therapeutic options remain limited
Our approach
The disease
A common degenerative disease affecting 600 million people worldwide
A long-acting intra-articular colchicine formulation
An extension of ARTHRELIS designed to provide sustained control of inflammation and pain directly within the affected joint
Few pharmacological options, with major limitations in efficacy and safety
The potential
A novel local therapeutic approach addressing a disease with a significant unmet medical need